SBIR/STTR Recipient

Chirp Microsystems, Inc.

Brief Description

Chirp Microsystems, Inc. designs, develops, and manufactures a line of extremely low power, ultrasonic 3D-sensing solutions for consumer electronics, smart homes, industrial automation, and much more. The company's ultrasonic 3D-sensing systems offer millimeter-accurate range information, based on machine learning and neural network algorithms and outperform infrared-based alternatives by every metric in real-world applications like consumer electronics, smart homes and industrial automation, enabling clients to avail the always-on sensing for...

Caribou Biosciences Inc.

Brief Description

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T cell platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases.

...

Ambi Robotics

Brief Description

Ambi Robotics offers advanced robot grasping software for logistics and warehouse order fulfillment, allowing robots to grasp a wide variety of objects.

Ambi Robotics grew from the Dexterity Network (Dex-Net) project at UC Berkeley and is led by Dr. Jeff Mahler and Professor Ken Goldberg, experts in robot grasping with a combined 50+ years of experience.

Formerly known as Ambidextrous.

Inventors

Ken Goldberg, Jeffrey Mahler, Matthew Matl

Company Founders

UC Berkeley Professor Ken Goldberg, Jeff Mahler (PhD ’18), Stephen McKinley (MS ’13, PhD ’...

Organos, Inc.

Brief Description Developer of cardiac micro physiological systems designed to offer three-dimensional (3D) human cardiac tissue models for advanced analysis. The company's data science ecosystem is used to illuminate the effects of compounds on human cardiac tissue, ranging from acute cardiotoxicity and safety pharmacology to chronic studies to predict drug-induced arrhythmia, thereby enabling the health industry to perform safer and cheaper drug development activities. Inventors

Kevin Healy, SoonGweon Hong, Luke Lee, Peter Loskill, Anurag Mathur Pia, Rodriguez Nunez...

Chiron Corporation

Brief Description

Chiron Corporation was an American biotechnology company engaged in biopharmaceuticals, vaccines and blood testing. Chiron was co-founded in 1981 by UC Berkeley biochemistry professor Edward Penhoet.

Timeline 1981. Company founded 1990. Company Initial Public Offering on NASDAQ under the ticker symbol of CHIR. 2006. Acquired by Novartis Inventors

Henry Chang, Felix Karim, Gerald Rubin, Marc Therrien, David Wassarman

Tularik Inc.

Brief Description

Tularik, Inc. engages in the discovery and development of orally available medicines that act through the regulation of gene expression. The company’s drugs include T67, T607, T131, T71, and T487. The T67 is an anti-cancer drug. The T607 would be used for treating gastric cancer and esophageal cancer. The T131 would be used for treating diabetes. The T71 would be used for treating obesity.

Tularik was co-founded in 1991 by UC Berkeley Professor Robert Tjian. Amgen acquired Tularik for $1.3 billion in 2004.

Timeline 1991. Company founded...

Resvita Biosciences

Brief Description

Resvita Biosciences seeks to restore and maintain the vitality of the skin by properly considering the skin microbiome as part of the human body. A harmless skin probiotic will continuously deliver the therapy that a body would to maintain skin health.

Through synthetic biology and metabolic engineering, the company's goal is to develop a safe and versatile skin microbial platform that can address the causes of skin aging and disease. Resvita Biosciences has a unique patented approach, a rich product pipeline, clear regulatory advantages, and an experienced...

Nurix

Brief Description

Nurix is pioneering rational drug design in the emerging field of protein regulation by targeting E2 conjugating enzymes and E3 ligases that control the Ubiquitin Proteasome System (UPS).

Regulation of protein stability by the UPS is modulated by the activity of these E2 and E3 enzymes, which control the tagging of proteins with ubiquitin for degradation by the proteasome. The human genome encodes approximately 1,000 different E3 ligases and 60 E2 enzymes. A number of these ligases recently have been shown to play key roles in human diseases, particularly in cancer...

Spotlight Therapeutics

Brief Description

Developer of next-generation gene editing therapeutics in a preclinical pipeline. The company creates programmable nucleases that selectively target and edit specific cell populations directly in the body. These engineered nucleases will enable direct intervention in vivo like a true administered biologic. Spotlight Therapeutics co-founders include Dr. Patrick Hsu, a UC Berkeley Assistant Professor of Bioengineering and co-founder of the Arc Institute.

Timeline 2017. Company founded. Inventors

Colleen McGourty, Lorena de Onate, Ross...

Imprint Energy, Inc.

Brief Description

Imprint Energy aims to reshape the battery landscape. Currently available battery technologies limit the pace of improvement in design and functionality of portable electronic devices. Imprint Energy will address these shortcomings with its breakthrough zinc-based rechargeable battery technology, ZincPolyª. ZincPolyª battery technology removes longstanding limitations on the rechargeability of zinc-based batteries and enables the production of ultrathin, flexible, high energy density rechargeable batteries for significantly lower cost and without the design limitations or...